The epigenome consists of a system of chemical tags that attach to our DNA and its associated molecules, switching genes on and off. But the system is not without glitches—and scientists think that the misplacement of these tags can cause disease. This idea has led to new drugs that aim to correct gene activity (and obliterate disease) by altering the proteins around which DNA winds. Cassandra Willyard examines whether this approach will unlock the long-awaited promise of epigenetic therapy.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Willyard, C. The saving switch. Nat Med 16, 18–21 (2010). https://doi.org/10.1038/nm0110-18
Issue Date:
DOI: https://doi.org/10.1038/nm0110-18
This article is cited by
-
Epigenetic modulation of the renal β-adrenergic–WNK4 pathway in salt-sensitive hypertension
Nature Medicine (2011)
-
Epigenetik in der Rheumatologie
Zeitschrift fĂĽr Rheumatologie (2011)